drugset / Trial / NCT00772889

Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly

NCT00772889

Phase 3 Completed 971 enrolled GlaxoSmithKline
Non-randomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this observer-blind clinical trial is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly. Subjects were previously vaccinated (NCT00529516).

Timeline

Start
2008-10-09
Primary completion
2009-12-15
Completion
2009-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK2186877A Vaccine Intramuscular
Comparator Influenza Virus Vaccine Vaccine Intramuscular

Indications